Amgen (AMGN) Q1 2026 Earnings Transcript

Amgen delivered a strong Q1 with 4% product sales growth, 45% non-GAAP operating margin, and $1.5 billion in free cash flow, while raising 2026 revenue guidance to $37.1 billion-$38.5 billion and EPS guidance to $21.70-$23.10. Key growth drivers were up 24% collectively to $5.6 billion, led by Repatha (+34% to $876 million), Evenity (+27% to $562 million), TEPEZZA (+29% to $490 million), and the oncology and biosimilars portfolios. Offseting positives include accelerating erosion in Prolia/XGEVA, higher cost-of-sales pressure, and ongoing IRS tax disputes and TAVNEOS regulatory uncertainty.

Analysis

AMGN’s core setup is no longer a one-product story; the important signal is that its growth mix is broad enough to absorb legacy erosion while preserving premium margins. That matters because the market tends to underwrite biologics platforms as if patent cliffs are binary, yet here the offset is a portfolio of adjacent, clinically differentiated franchises that can keep commercial leverage high even as cost-of-sales drifts up. The guidance raise looks less like a one-quarter beat and more like validation that the company can self-fund both pipeline optionality and capital returns without sacrificing operating discipline.

The bigger second-order implication is competitive: Amgen is trying to turn convenience, access, and real-world evidence into durable switching costs in categories where incumbents still rely on habit and reimbursement inertia. Meritide is the most asymmetric asset in that mix because the investment case is not simply obesity participation; it is whether a lower-frequency regimen can become the preferred “maintenance” layer after the initial GLP-1 wave, which would make it a churn-capture story rather than a head-to-head pure share grab. If that positioning works, the upside is not just new revenue but a structurally better duration profile for the obesity franchise than weekly competitors.

The main risks are calendar-driven, not macro-driven: the next 3–9 months should be dominated by legal/tax noise and by whether pipeline enthusiasm can survive actual Phase 3 readouts. The IRS issue is the easiest near-term overhang to compress the multiple, while the Tavneos regulatory cloud and accelerated Prolia/XGEVA erosion create a runway of “known unknowns” that can cap sentiment even if fundamentals hold. The contrarian view is that the market may be underestimating how much of 2026 guidance is already insulated by launch diversity, but overestimating the immediacy of Meritide monetization; that means the stock can work before obesity data, yet the rerating likely requires proof that new product growth can persist into 2027 without relying on one catalyst.

Key Decisions for Investors

• Long AMGN versus short NVS or SNY over the next 3-6 months: AMGN has the cleaner self-help story and better visible revenue offsets to exclusivity loss, while the shorts remain more exposed to pipeline disappointment and slower commercial re-acceleration.
• Buy AMGN on any legal/tax-driven pullback of 5-8%: the IRS draft adjustment is a headline risk, but the market is likely to overdiscount a non-final issue before any economic impact is quantified.
• Use a call spread in AMGN into the next 6-9 months (e.g., 1x2 or vertical) to express upside from meritide/pipeline optionality while limiting downside if obesity data slips; best risk/reward if implied vol rises on readout expectations.
• Pair long AMGN / short a basket of slower-growth large-cap pharma with heavier legacy erosion exposure (e.g., NVS, SNY) for a 6-12 month relative-value trade; thesis is commercial execution and pipeline breadth should compress the valuation gap.
• If Meritide Phase 3 maintenance/switch data read positively, add to AMGN on confirmation rather than anticipation; the real monetization catalyst is likely label breadth and switching economics, not just initial efficacy.